A EFFACER all cancer  

  basal cell carcinoma  

  biliary tract cancer (BTC)  

billiary tract cancer - (neo)adjuvant (NA)  

billiary tract cancer - 1st line (L1)  

billiary tract cancer - 2nd line (L2)  

cholangiocarcinoma  

  breast cancer (BC)  

breast cancer - adjuvant  

breast cancer - HER2-positive  

es-BC - HER2 positive - (neo)adjuvant (NA)  

la/mBC - HER2 positive  

la/mBC - HER2 positive - (neo)adjuvant (NA)  

la/mBC - HER2 positive - 1st Line (L1)  

la/mBC - HER2 positive - 2nd Line (L2)  

breast cancer - HR positive  

es-BC - HR positive - (neo)adjuvant (NA)  

es-BC - HR-positive - 1st line (L1)  

la/mBC - HR positive  

la/mBC - HR positive - (neo)adjuvant (NA)  

la/mBC - HR positive - NA - PIK3CA mutant  

la/mBC - HR-positive - 1st line (L1)  

la/mBC - HR positive - L1 - PIK3CA mutant  

la/mBC - HR-positive - 2nd line (L2)  

la/mBC - HR positive - L2 - all population  

la/mBC - HR positive - L2 - PIK3CA mutant  

breast cancer - triple negative  

breast cancer - triple negative metastatic  

mBC - Triple negative (TNBC) - (neo)adjuvant (NA)  

mBC - Triple negative (TNBC) - 1st Line (L1)  

mBC - TNBC - L1 - all population  

mBC - TNBC - L1 - PDL1 positive  

mBC-Triple negative (TNBC) - 2nd Line (L2)  

mBC - TNBC - L2 - all population  

mBC - TNBC - L2 - PDL1 positive  

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)  

es-BC - TNBC - NA - all population  

es-BC - TNBC - NA - PDL1 positive  

es-BC - Triple negatif (TNBC) - 1st line (L1)  

breast cancer HER 2 negative  

es-BC - HER2 negative - (neo)adjuvant (NA)  

mBC - HER 2 negative  

metastatic/advanced - breast cancer (mBC)  

  cervical cancer (CC)  

  classical Hodgkin lymphoma (cHL)  

refractory classic Hodgkin lymphoma (R/R cHL)  

R/R cHL - second line or more (L2)  

  colorectal cancer (CRC)  

locally advanced rectal cancer (LARC)  

metastatic/advanced - colorectal cancer (mCRC)  

mCRC - (neo)adjuvant (NA)  

mCRC - 1st line (L1)  

mCRC - 2nd line (L2)  

  endometrial cancer  

endometrial cancer - (neo)adjuvant (NA)  

  esophageal cancer (EC)  

locally advanced - esophageal cancer (laEC)  

laEC - Neo(adjuvant) (NA)  

metastatic/advanced - esophageal cancer (mEC)  

mEC - (neo)adjuvant (NA)  

mEC - 1st line (L1)  

mEC - 2nd line (L2)  

  gastric or gastroesophageal junction cancer (GC)  

locally advanced (laGC)  

laGC - (neo)adjuvant (NA)  

metastatic/advanced mGC or mGEJC  

mGC or mGEJC - 1st line (L1)  

mGC or mGEJC - L1 - all population  

mGC or mGEJC - L1 - HER2 neg/PDL1 positive  

mGC or mGEJC - L1 - HER2 negative  

mGC or mGEJC - L1 - HER2 positive  

mGC or mGEJC - L1 - PDL1 positive  

mGC or mGEJC - 2nd Line (L2)  

mGC or mGEJC - L2 - all population  

mGC or mGEJC - L2 - PDL1 positive  

mGC or mGEJC - maintenance (M)  

mGC or mGEJC - M - HER2 negative  

mGC or mGEJC - M - HER2 neg/PDL1 positive  

  gene alteration defined cancer  

BRAF gene alteration defined cancer  

BRCA1/2 gene alteration defined cancer  

EGFR gene alteration defined cancer  

EGFR exon 20 insertion mutation  

FGFR (2/3) gene alteration defined cancer  

KRAS gene alteration defined cancer  

MET gene alteration defined cancer  

NTRK gene alteration  

RET gene alteration defined cancer  

  glioblastoma (GB)  

metastatic glioblastoma (mGB) - 1st line (L1)  

metastatic glioblastoma (mGB) - 2nd line (L2)  

  head and neck cancer squamous cell cancer (HNSCC)  

locally advanced (laHNSCC)  

laHNSCC - (neo)adjuvant (NA)  

laHNSCC - 1st line (L1)  

laHNSCC - 2nd line (L2)  

metastatic-recurrent HNSCC (mHNSCC)  

mHNSCC - (neo)adjuvant (NA)  

mHNSCC - 1st line (L1)  

mHNSCC - L1 - all population  

mHNSCC - L1 - PDL1 positive  

mHNSCC - 2nd line (L2)  

mHNSCC - L2 - all population  

mHNSCC - L2 - PDL1 negative  

mHNSCC - L2 - PDL1 positive  

  hepatocell cancer (HCC)  

early HCC - (neo)adjuvant (NA)  

metastatic/advanced hepatocellular cancer (mHCC)  

mHCC - (neo)adjuvant (NA)  

mHCC - 1st line (L1)  

mHCC - 2nd line (L2)  

  lung cancer : non small cell (NSCLC)  

early NSCLC - (neo)adjuvant (NA)  

eNSCLC - NA - all population  

eNSCLC - NA - EGFR mutant  

early NSCLC - 1st line (L1)  

locally advanced NSCLC - (neo)adjuvant (NA)  

laNSCLC - NA - all population  

locally advanced NSCLC - maintenance (M)  

laNSCLC - M - all population  

laNSCLC - M - EGFR mutant  

metastatic/adv NSCLC (mNSCLC) - (neo)adjuvant (NA)  

mNSCLC - NA - all population  

metastatic/adv NSCLC (mNSCLC) - maintenance (M)  

mNSCLC - M - all population  

mNSCLC - M - EGFR mutant  

mNSCLC - M - EGFR wild type  

mNSCLC - M - PDL1 positive  

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)  

mNSCLC - L1 - all population  

mNSCLC - L1 - EGFR mutant  

mNSCLC - L1 - PDL1 negative  

mNSCLC - L1 - PDL1 positive  

mNSCLC - L1 - TMB>10Mb  

non squamous cell - mNSCLC - L1  

non squamous - mNSCLC - L1 - all population  

non squamous - mNSCLC - L1 - PDL1 positive  

non squamous - mNSCLC - L1 - Wild Type (WT)  

squamous cell - mNSCLC - L1  

squamous - mNSCLC - L1 - all population  

squamous - mNSCLC - L1 - PDL1 positive  

squamous - mNSCLC - L1 - Wild Type (WT)  

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)  

mNSCLC - L2 - adenocarcinoma cell  

mNSCLC - L2 - all population  

mNSCLC - L2 - EGFR high  

mNSCLC - L2 - EGFR mutant  

mNSCLC - L2 - EGFR wild type  

mNSCLC - L2 - KRAS mutant  

mNSCLC - L2 - KRAS wild type  

mNSCLC - L2 - PDL1 negative  

mNSCLC - L2 - PDL1 positive  

non squamous cell - mNSCLC - L2  

non squamous - mNSCLC - L2 - all population  

non squamous - mNSCLC - L2 - EGFR mutant  

non squamous - mNSCLC - L2 - PDL1 positive  

non squamous - mNSCLC - L2 - wild type (WT)  

squamous cell - mNSCLC - L2  

squamous - mNSCLC - L2 - all population  

squamous - mNSCLC - L2 - PDL1 positive  

NSCLC adjuvant setting  

NSCLC neoadjuvant setting  

  lung cancer : small cell (SCLC)  

Extensive stage SCLC (Es-SCLC)  

Extensive stage SCLC (Es-SCLC) - maintenance (M)  

Extensive stage SCLC (Es-SCLC) - 1st Line (L1)  

Extensive stage SCLC (Es-SCLC) - 2nd line (L2)  

limited stage SCLC (ls-SCLC)  

limited stage SCLC (ls-SCLC) - maintenance (M)  

limited stage SCLC (ls-SCLC) - 2nd Line (L2)  

  melanoma (ML)  

metastatic/adv melanoma (mML)  

mML - (neo)adjuvant (NA)  

mML - NA - all population  

mML - NA - PDL1 positive  

mML - 1st line (L1)  

mML - L1 - all population  

mML - L1 - BRAF mutant  

mML - L1 - BRAF wild  

mML - 2nd line (L2)  

mML - L2 - all population  

mML - L2 - BRAF mutant  

  mesothelioma (MS)  

malignant mesothelioma (mMS) - (neo)adjuvant (NA)  

malignant mesothelioma (mMS) - 1st line (L1)  

malignant mesothelioma (mMS) - 2nd line (L2)  

  multiple myeloma  

multiple myeloma - 1st line (L1)  

multiple myeloma - 2nd line (L2)  

  myofibroblastic tumors  

  neurofibroma  

  neutropenia  

  new pathology  

  osteosarcoma  

  ovarian cancer (OC)  

metastatic/advanced OC (mOC) - (neo)adjuvant (NA)  

metastatic/advanced OC (mOC) - 1st line (L1)  

mOC - L1 - all population  

mOC - L1 - PDL1 positive  

metastatic/advanced OC (mOC) - 2nd line (L2)  

metastatic/advanced OC (mOC) - maintenance (M)  

  pancreatic ductal adenocarcinoma  

  PIK3CA-related overgrowth spectrum  

  prostate cancer (PC)  

castration-resistant prostate cancer (CRPC)  

metastatic (mCRPC) - 1st line (L1)  

metastatic (mCRPC) - 2nd line (L2)  

metastatic, hormone-sensitive prostate cancer  

  renal cell cancer (RCC)  

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)  

metastatic/advanced RCC (mRCC) - 1st line (L1)  

mRCC - L1 - PDL1 negative  

mRCC - L1 - PDL1 positive  

metastatic/advanced RCC (mRCC) - 2nd line (L2)  

  sarcomas  

  thyroid cancer  

  urothelial cancer (UC) - bladder cancer (BC)  

metastatic/advanced UC (mUC) - 1st Line (L1)  

mUC - L1 - all population  

mUC - L1 - PDL1 positive  

metastatic/advanced UC (mUC) - 2nd Line (L2)  

mUC - L2 - all population  

mUC - L2 - PDL1 positive  

metastatic/advanced UC (mUC) - maintenance (M)  

mUC - M - all population  

mUC - M - PDL1 positive  

muscular invasive bladder cancer (MIBC)  

MIBC - (neo)adjuvant (NA)  

MIBC - NA - all population  

MIBC - NA - PDL1 positive  

non-muscle-invasive BC (NMIBC)  

NMIBC - (neo)adjuvant (NA)  

NMIBC - 1st line (L1)  

NMIBC - 2nd line (L2)